Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine.

IF 4.1 2区医学 Q1 CLINICAL NEUROLOGY

Pain and Therapy Pub Date : 2025-06-27 DOI:10.1007/s40122-025-00757-z

Maureen A Moriarty, Carol A Barch

引用次数: 0

Abstract

With 80% of migraines diagnosed and managed by primary care clinicians, a knowledge of standard of care and novel therapy is essential for those caring for people with this chronic disease. This review describes a new class of medication, calcitonin gene-related protein (CGRP) antagonists, known as gepants and their use with the focus on the general class of gepants rather than any specific type. These medications were developed specifically for acute and preventive treatment of migraine and appear to be more tolerable with fewer side effects than standard-of-care medications. Previous standard-of-care medications were developed for managing non-migraine disorders but were found to demonstrate efficacy in migraine control despite not directly targeting migraine pathophysiology. Evidence-informed review of the literature and real-world application of gepants is presented to provide a solid understanding of the class and guidance for use.

查看原文本刊更多论文

初级保健中的患者：偏头痛急性和预防性治疗的针对性方法。

由于80%的偏头痛是由初级保健临床医生诊断和管理的，因此，对于那些照顾这种慢性疾病患者的人来说，了解标准护理和新疗法至关重要。本文综述了一类新的药物，降钙素基因相关蛋白（CGRP）拮抗剂，被称为gepants及其应用，重点介绍了一般类型的gepants，而不是任何特定类型。这些药物是专门为偏头痛的急性和预防性治疗而开发的，与标准治疗药物相比，它们似乎更容易耐受，副作用也更少。以前的标准治疗药物是为治疗非偏头痛疾病而开发的，尽管没有直接针对偏头痛的病理生理，但它们在偏头痛控制方面显示出疗效。对文献和实际应用的循证回顾，提供了对该类的扎实理解和使用指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pain and Therapy CLINICAL NEUROLOGY-

CiteScore

6.60

自引率

5.00%

发文量

110

审稿时长

6 weeks

期刊介绍： Pain and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pain therapies and pain-related devices. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, acute pain, cancer pain, chronic pain, headache and migraine, neuropathic pain, opioids, palliative care and pain ethics, peri- and post-operative pain as well as rheumatic pain and fibromyalgia. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Pain and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.